4-(4-Hydroxyphenyl)semicarbazide | 73469-92-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-Hydroxyphenyl)semicarbazide
• 英文别名: 1-amino-3-(4-hydroxyphenyl)urea
• CAS: 73469-92-8
• 化学式: C₇H₉N₃O₂
• 分子量: 167.167
• InChiKey: NTSXSCNGNVDTJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  87.4
• 氢给体数：
  4
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-ylamino)acetic acid 、 4-(4-Hydroxyphenyl)semicarbazide 在 三氯氧磷 作用下， 以73%的产率得到4-[(5-[4-hydroxylphenylamino]-1,3,4-oxadiazol-2-yl)methylamino]-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one
  参考文献：
  名称：

  Discovery of novel antitubercular 1,5-dimethyl-2-phenyl-4-([5-(arylamino)-1,3,4-oxadiazol-2-yl]methylamino)-1,2-dihydro-3H-pyrazol-3-one analogues

  摘要：

  In search of potential therapeutics for tuberculosis, we describe herewith the synthesis, characterization and antimycobacterial activity of 1,5-dimethyl-2-phenyl-4-([5-(arylamino)-1,3,4-oxadiazol-2-yl]methylamino)-1,2-dihydro-3H-pyrazol-3-one analogues. Among the synthesized compounds, 4-1(5-1( 4-fluorophenylamino[-1,3,4-oxadiazol-2-yl)methylamino]-1,2-dihydro-1,5-dimethyl-2-Phenylpyrazol-3-one (4a) was found to be the most promising compound active against Mycobacterium tuberculosis H(37)Rv and isoniazid resistant M. tuberculosis with minimum inhibitory concentrations, 0.78 and 3.12 mu g/mL, respectively, free from any cytotoxicity (>62.5 mu g/mL). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.014
• 作为产物：
  描述：

  N(hydroxy-4 phenyl) carbamate de phenyle 在 hydrazine hydrate 作用下， 以 水 、 乙腈 为溶剂， 反应 3.0h， 以97%的产率得到4-(4-Hydroxyphenyl)semicarbazide
  参考文献：
  名称：

  通过氨基甲酸苯酯由相应的胺和肼制备取代的氨基脲

  摘要：

  开发了一种简单的合成方法，用于将胺和肼转化为取代的氨基脲。所需的胺和氯甲酸苯酯之间最初的缩合成氨基甲酸苯酯，然后在碱性条件下加入肼。该反应可耐受各种官能团，条件温和，收率高。

  DOI：

  10.1016/j.tetlet.2014.01.052

文献信息

• Method of processing a silver halide color photographic material and a
  申请人：Fuji Photo Film Co., Ltd.

  公开号：US05064751A1

  公开（公告）日：1991-11-12

  A method for processing a silver halide color photographic material including the step of developing the silver halide color photographic material with a color developing solution containing at least one aromatic primary amine developing agent and at least one hydrazide represented by the following formula (I) or (II) R.sup.1 --X.sup.1 --NHNH--R.sup.2 (I) in which X.sup.1 represents --CO--, --SO.sub.2 -- or ##STR1## R.sup.1 represents a hydroxyl group, a hydroxyamino group, carbamoyl group, a hydrazinocarbonyl group, an amino group, or a hydrazino group; and R.sup.2 represents a hydrogen atom, an alkyl group, or an aryl group; provided that the R.sup.1 or R.sup.2 groups of at least two of the hydrazide groups may be linked to form a dimer or higher polymer of the hydrazide. R.sup.3 --X.sup.2 --NHNH--R.sup.4 (II) in which X.sup.2 represents --CO-- or --SO.sub.2 --; R.sup.3 represents a hydrogen atom, an alkyl group, an aryl group, a heterocyclic group, an alkoxy group, or an aryloxy group; and R.sup.4 represents a hydrogen atom, an alkyl group or an aryl group; provided that the R.sup.3 or R.sup.4 groups of at least two of the hydrazide groups may be linked to form a dimer or higher polymer of the hydrazide. The method provides increased developer stability and reduced fog formation, particularly in continuous processing.

  一种处理银卤化物彩色照相材料的方法，包括以下步骤：用含有至少一种芳香族原始胺显影剂和至少一种由以下公式（I）或（II）表示的肼类化合物的显色显影溶液显影银卤化物彩色照相材料。其中，X1代表—CO—、—SO2—或##STR1##，R1代表羟基、羟基氨基、氨甲酰基、肼甲酰基、氨基或肼基；R2代表氢原子、烷基或芳基；但至少两个肼基的R1或R2基团可连接形成肼的二聚体或更高聚合物。R3—X2—NHNH—R4（II）其中，X2代表—CO—或—SO2—，R3代表氢原子、烷基、芳基、杂环基、烷氧基或芳氧基；R4代表氢原子、烷基或芳基；但至少两个肼基的R3或R4基团可连接形成肼的二聚体或更高聚合物。该方法提供了增加显影剂稳定性和减少雾化现象的效果，特别是在连续处理中。
• Synthesis of N-aryl and N-arylcarbamoylamino derivatives of 1,3-diazinane-5-carboxamide and their activity against glioblastoma LN-229 cell line
  作者：Rebecca J. Hron、Branko S. Jursic、Donna M. Neumann

  DOI：10.1016/j.bmc.2016.09.074

  日期：2016.12

  Six structural motifs based on the initial (lead) structure of merbarone were designed, prepared, and tested against the glioblastoma LN-229 cell line. Three different structural moieties were modified in the search for optimal glioblastoma activity: the 1,3-diazinane moiety, the aryl moiety, and the heteroatom linker. Calculated molecular descriptors such as lipophilicity (ClogP), acidic strength (calculated pK(a)), and polar surface area (PSA) were used to design a diverse structural library of these compounds. From six different structural motifs and 136 compounds, a handful of examples with moderate (100 mu g/ml), good (10 mu g/ml) and excellent (1 mu g/ml) glioblastoma activity were elucidated. (C) 2016 Published by Elsevier Ltd.
• Kramer, Claus-Ruediger; Beck, Lothar, Zeitschrift fur Chemie, 1980, vol. 20, # 1, p. 25 - 26
  作者：Kramer, Claus-Ruediger、Beck, Lothar

  DOI：——

  日期：——
• [EN] INDAN-1,3-DIONE AND INDAN-1,2,3-TRIONE DERIVATIVES, PROCESSES FOR THE PREPARATION OF SAME AND THEIR APPLICATION AS THERAPEUTIC AGENTS<br/>[FR] DERIVES D'INDANE-1,3-DIONE ET D'INDANE-1,2,3-TRIONE, LEURS PROCEDES DE PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
  申请人：INNOTHERA

  公开号：WO1993020045A1

  公开（公告）日：1993-10-14

  (EN) Compounds of formula (I) used as therapeutic agents. R2 and R3 are independently H, C1-C4 alkoxy or OH and (A, B) = (oxygen, oxygen) in which case either R or R1 is OH, halogen, secondary amino or tertiary amine while the other denotes NHNHCONHR4 or R and R1 together form =N-NH-CX-NHR5, =N-NH-CX-N(phenyl)2, =N-NH-CX-NH-NH-R5, =N-NH-C(SCH3)=N-R6 or =N-N=C(SCH3)-NH-R6; or (A, B) = (N-OH, oxygen) in which case R and R1 together form =N-NH-CX-NHR5 or =N-NH-CX-N(phenyl)2; or (A, B) = (N-NH-CX-NHR5, oxygen) in which case R and R1 together form =N-NH-CX-NHR5; or (A, B) = (N-OH, N-OH) in which case R and R1 together form =N-NH-CX-NHR5 or =N-NH-CX-N(phenyl)2.(FR) Composés utiles en thérapeutique de formule (I) dans laquelle R2 et R3 représentent indépendamment l'un de l'autre H, alkoxy en C1-C4 ou OH et (A, B) = (oxygène, oxygène), auquel cas l'un parmi R et R1 représente OH, halogène, amino secondaire ou amine tertiaire et l'autre représente NHNHCONHR4 ou bien R et R1 forment ensemble =N-NH-CX-NHR5, =N-NH-CX-N(phényle)2, =N-NH-CX-NH-NH-R5, =N-NH-C(SCH3)=N-R6 ou =N-N=C(SCH3)-NH-R6; ou (A, B) = (N-OH, oxygène), auquel cas R et R1 forment ensemble =N-NH-CX-NHR5 ou =N-NH-CX-N(phényle)2; ou (A, B) = (N-NH-CX-NHR5, oxygène), auquel cas R et R1 forment ensemble =N-NH-CX-NHR5; ou (A, B) = (N-OH, N-OH), auquel cas R et R1 forment ensemble =N-NH-CX-NHR5 ou =N-NH-CX-N(phényle)2.